"I am proud to say that despite an exponential increase in the demand for some medicines, the research-based pharmaceutical industry was able to increase capacity, in some cases by as much as 300-400 percent, and manage supply issues to the point that not a single EFPIA member reported disruption to supply of finished products during that extremely challenging period."
Lars Fruergaard Jørgensen, President and CEO at Novo Nordisk and First Vice-President at EFPIA, reflects on what Covid-19 thought us and what we can do to avoid shortages of medicines in the future.
Policy makers with a personal or heightened understanding of the ravages of cancer often have greater empathy with the...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.